In this issue:
Sitagliptin and narrow-band UVB for moderate psoriasis
Shared genetic loci between psoriasis and type 2 diabetes
Societal impact for patients with psoriasis
Psoriasis severity and cardiometabolic risk factors
Biologic treatment algorithms for moderate-to-severe psoriasis
Drug survival of biologics for psoriasis treatment
Comparative efficacy of biologics and oral therapies for plaque psoriasis
Apremilast in biologic-naive patients with moderate psoriasis
Prolonged low-dose ciclosporin in an Asian population
One-step dose reduction with adalimumab, etanercept and ustekinuma
Please login below to download this issue (PDF)